Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.64 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.64 |
| ▸ | CA12 | O43570 | 3/20 | 0.39 |
| ▸ | CA1 | P00915 | 3/20 | 0.39 |
| ▸ | CA2 | P00918 | 3/20 | 0.39 |
| ▸ | CA9 | Q16790 | 3/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13027731 | 0.92 | MEN1 (0.71) | MEN1PABPC1KMT2ACA12CA1 | |
| SCHEMBL13028025 | 0.89 | MEN1 (0.63) | MEN1PABPC1KMT2ACA12CA1 | |
| SCHEMBL2891553 | 0.88 | MEN1 (0.66) | MEN1PABPC1KMT2ACA12CA1 | |
| Mitozolomide SCHEMBL97695 | 0.86 | MEN1 (0.64) | MEN1PABPC1KMT2ACA12CA1 | |
| SCHEMBL13028036 | 0.86 | MEN1 (0.64) | MEN1PABPC1KMT2ACA12CA1 | |
| SCHEMBL2892060 | 0.86 | MEN1 (0.64) | MEN1PABPC1KMT2ACA12CA1 | |
| SCHEMBL3336560 | 0.86 | MEN1 (0.68) | MEN1PABPC1KMT2ACA12CA1 | |
| SCHEMBL3334065 | 0.86 | MEN1 (0.64) | MEN1PABPC1KMT2ACA12CA1 | |
| SCHEMBL2885923 | 0.85 | MEN1 (0.63) | MEN1PABPC1KMT2ACA12CA1 | |
| SCHEMBL3337129 | 0.85 | MEN1 (0.63) | MEN1PABPC1KMT2ACA12CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230212202-A1 | TREATMENT OF MGMT DEFICIENT CANCER WITH 2-FLUOROETHYL-SUBSTITUTED NITROSOUREAS AND OTHER COMPOUNDS | YALE UNIVERSITY | 2023-07-06 | — | — | US | disclosed |
| US-8450479-B2 | 3-substituted-4-oxo-3,4-dihydro-imidazo[5,1-d][1,2,3,5-tetrazine-8-carboxylic acid amides and their use | PHARMINOX LIMITED (GB) | 2013-05-28 | — | — | US | disclosed |
| US-8450479-B2 | 3-substituted-4-oxo-3,4-dihydro-imidazo[5,1-d][1,2,3,5-tetrazine-8-carboxylic acid amides and their use | PHARMINOX LIMITED (GB) | 2013-05-28 | — | — | US | disclosed |
| US-20100286088-A1 | 3-Substituted-4-Oxo-3,4-Dihydro-Imidazo[5,1-d][1,2,3,5-Tetrazine-8-Carboxylic Acid Amides and Their Use | PHARMINOX LIMITED (GB) | 2010-11-11 | — | — | US | disclosed |
| US-20100286088-A1 | 3-Substituted-4-Oxo-3,4-Dihydro-Imidazo[5,1-d][1,2,3,5-Tetrazine-8-Carboxylic Acid Amides and Their Use | PHARMINOX LIMITED (GB) | 2010-11-11 | — | — | US | disclosed |
| WO-2009077741-A2 | 3-SUBSTITUTED-4-OXO-3,4-DIHYDRO-IMIDAZO-[5,1-D][1,2,3,5-TETRAZINE-8-CARBOXYLIC ACID AMIDES AND THEIR USE | PHARMINOX LIMITED (GB) | 2009-06-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100286088-A1 | 3-Substituted-4-Oxo-3,4-Dihydro-Imidazo[5,1-d][1,2,3,5-Tetrazine-8-Carboxylic Acid Amides and Their Use | MKI67, CCNI, CDK4 | MEN1 3049/4885PABPC1 3755/4885KMT2A 209/4885 |
| US-20230212202-A1 | TREATMENT OF MGMT DEFICIENT CANCER WITH 2-FLUOROETHYL-SUBSTITUTED NITROSOUREAS AND OTHER COMPOUNDS | MSH2, MGMT, MSH6 | MEN1 542/4885PABPC1 1226/4885KMT2A 267/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.